Silexion Therapeutics (NASDAQ:SLXN) Stock Price Down 7.2% – Here’s What Happened

Silexion Therapeutics Corp (NASDAQ:SLXN)’s share price dropped 7.2% on Thursday . The company traded as low as $1.27 and last traded at $1.28. Approximately 484,120 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 6,368,076 shares. The stock had previously closed at $1.38.

Silexion Therapeutics Price Performance

The stock’s 50-day moving average is $1.34 and its two-hundred day moving average is $3.30.

Institutional Trading of Silexion Therapeutics

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Wildcat Capital Management LLC purchased a new stake in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics accounts for about 0.3% of Wildcat Capital Management LLC’s holdings, making the stock its 7th largest position. Wildcat Capital Management LLC owned about 7.38% of Silexion Therapeutics at the end of the most recent quarter. 10.95% of the stock is currently owned by institutional investors and hedge funds.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.